Abstract
Sipuleucel-T is an autologous cellular immunotherapy designed to stimulate an immune response against prostate cancer. It is made from peripheral blood mononuclear cells (PBMCs) cultured ex vivo with a recombinant fusion antigen, PA2024 comprising prostatic acid phosphatase [PAP] linked to granulocyte-macrophage colony-stimulating factor [GM-CSF]). Sipuleucel-T has demonstrated improved overall survival (OS) in men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (mCRPC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
